

# EXHIBIT A

<u>Exhibit</u>	<u>Description</u>	<u>Category</u>
553	Asch Deposition, 05/02/2016 - Exhibit 203 - 9/14/2002 Memo from Thomas Kinst to Recovery Filter Design History File Re. Recovery Filter Compassionate Use, Subject: "Conference call with Bard Peripheral Technologies regarding clinical assessment of Recovery Filter removal #5"	2
709	Brauer, 08/02/2017, Exhibit 1046 - Bard Simon Nitinol Filter, Postmarket Surveillance Study Amendment, August 10, 2014	2
876	Chanduszko Deposition, 04/23/2015 - Exhibit 17 - Pages 30-44 of Notebook No. 7013, Project: Recovery Filter Arm Fatigue Testing	1
905	Ciavarella Deposition, 03/01/2011 - Exhibit 07 - 12/20-12/23/2005 E-mail exchange b/w Walcott and Ciavarella Re. "G2 Caudal Migrations"	3
927	Ciavarella Deposition, 11/12/2013 - Exhibit 35 - Health Hazard Evaluation Memo from Ciavarella to Uelmen Re. "Recovery Filter - Consultant's report", dated 12/17/2004	2
945	Cohen, 01/25/2017, Exhibit 736 - Monthly Report, IVC Filters/Covered Stents, Janet Hudnall, April, 2004	2
1062	Edwards Deposition, 01/20/2014 - Exhibit 14 - BPV PowerPoint presentation entitled "BPV/AngioMed New Product Development Review Meeting - April 26, 2004"	2
1216	Ganser Deposition, 10/11/2016 - Exhibit 526 - Regulatory Affairs Manual Re. "Product Remedial Actions", RA-STD-002 Rev. 08, dated 10/12/2000	4
1221	Ganser Deposition, 10/11/2016 - Exhibit 533 - 2/15/2006 Health Hazard Evaluation from David Ciavarella to Gin Schulz Re. "G2 Inferior Vena Cava Filter - Migration"	4
1222	Ganser Deposition, 10/11/2016 - Exhibit 534 - PowerPoint Presentation for a meeting to analyze EVEREST and MAUDE data and provide justifications for proposed changes to G2 filter	2, 3
1295	Graves Deposition, 02/27/2014 - Exhibit 10 - 3/23/2006 E-mail exchange b/w Mickey Graves and Charlie Simpson, FEA on G2, regarding Historical FEA analysis	2
1517	Kessler Report - Based on the Fishbone analysis insufficient caudal anchoring is likely the root cause of caudal tilts and caudal migrations, and indirectly of penetrations and fractures."	1, 2

1578	Kessler Report ETR-06-28-29, revision 0, project #8049, Caudal Migration Test Method Development and G2 Filter Resistance Test Report, 11/27/06	1, 2
1680	McDonald Deposition, 07/29/2016 - Exhibit 21 - 7/13/2015 Warning Letter from the FDA regarding the 11/25/2014 Inspection of the C.R. Bard facility in NY and the 11/18/2014-1/5/2015 Inspection of the BPV facility in AZ	4
1945	Schulz Deposition, 01/30/2014 - Exhibit 16 - 10/1/2006 E-mail from Nataile Wong to Several Re. "Fracture Docs"	3
1946	Schulz Deposition, 01/30/2014 - Exhibit 17 - 2/2/2006 E-mail from Gin Schulz to Several Re. "Minutes"	3
1951	Schulz Deposition, 01/30/2014 - Exhibit 5 - 1/31/2005 Memo from Peter Palermo to Kerry Chunko Re. "Quality Plan 2005"	2
2048	Sullivan Deposition, 09/16/2016 - Exhibit 437 - Document entitled "Failure Investigations/R002 History Review"	2, 3
2052	Sullivan Deposition, 09/16/2016 - Exhibit 446 - Draft of PowerPoint Presentation entitled "G2 and G2X Fracture Analysis", dated 11/30/2008	3
2059	Tessmer Deposition, 06/12/2013 - Exhibit 02 - Project Status Report Form for the Recovery Filter, Project No. 7081, initiated 7/1/2002 with the goal to "Investigate Migration"; FM0700160, Rev. 1.	2
2090	Tillman, 08/04/2017, Exhibit 1064 - NMT Medical, Inc. Document	2
2217	Williamson Deposition, 09/07/2016 - Exhibit 105 - Cover page entitled "Attachment 1.14", followed by the 1/23/2015 Memo from Ludwig to Chad Modra Re. "IVC Filters Retrospective Review", detailing the 2-year review of 939 filter complaints from 1/2013 to 1/2015, with a chart detailing whether the MDR classification changed for any complaints	2, 3
2243	Wong Deposition, 10/18/2016 - Exhibit 537 - 4/23/2004 E-mail from John Lehmann to Carr and Uelmen Re. "Draft data set for statistician"	3
2245	Wong Deposition, 10/18/2016 - Exhibit 540 - Confidential PowerPoint Presentation entitled "Recovery (Gen 1) - Fracture and Migration Complaint Update," dated 6/20/2006	3
2246	Wong Deposition, 10/18/2016 - Exhibit 541 - 8/4/2006 E-mail from Natalie Wong to Gin Schulz Re. "Updated RNF Draft Report"	3

2247	Wong Deposition, 10/18/2016 - Exhibit 542 - 12/2/2009 E-mail exchange b/w Sandy Kerns and Natalie Wong Re. "Filter Fractures"	3
2248	Wong Deposition, 10/18/2016 - Exhibit 543 - PAT PowerPoint Presentation entitled "G2 Caudal Migration Update," dated 3/2/2006, which Wong circulated via e-mail on 3/2/2006 to several for the presentation that afternoon	3
2249	Wong Deposition, 10/18/2016 - Exhibit 544 - 5/18/2006 Natalie Wong meeting documents, email re "Caudal Investigation" with attachments of G2 Caudal Report 05.18.06 and Caudal Pre-PAT minutes	3
2250	Wong Deposition, 10/18/2016 - Exhibit 545 - BPV's Failure Investigation Report on the G2 Filter - Caudal Migration, FIR-06-01-01, unsigned and forwarded by Wong to Gin Schulz for her review, in anticipation of the Friday deadline	2, 3
2251	Wong Deposition, 10/18/2016 - Exhibit 547 - 4/10/2006 High Importance E-mail from Cindi Walcott to Allen, Schulz, and McDermott Re. "FW: FDA Request for Information"	4
2252	Wong Deposition, 10/18/2016 - Exhibit 548 - 9/25/2007 E-mail from John Lehmann to John Van Vleet and John Reviere Re. "EVEREST FSR rev H and supporting redlines	1
2253	Wong Deposition, 10/18/2016 - Exhibit 549 - 5/27/2004 E-mail from Natalie Wong to Doug Uelmen Re. "Recovery Stats"	3
4327	Monthly Global PV Report - January 2006, date of memo, 02/10/2006	2, 3
5022	RD-LNB-087 Laboratory Notebook	2
5037	ETR-05-02-02 (Effects of Changes to the Recovery Filter & The Femoral Delivery System on Filter Stresses Based on FEA Analysis)	2
5189	July 10, 2002 IMPRA Recovery Permanent Special 510(k) (K022236)	4
5195	Nov. 30, 2004 Letter FDA to BPV re Recovery IFU and DDL	4
5232	RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116	1, 3
5233	RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)	1
5290	TD-00456 (EVEREST Study Final Report)	1

5296	G2 Filter Product Performance Specification, v.2	1
5301	ETR-05-01-06 Animal Model Evaluation of Recovery Filter G1A Femoral System Report	1
5302	TPR 05-01-13 G1A Recovery Filter Femoral System Design Verification and Validation Protocol	1
5303	ETR-05-02-05 (G2® DV&V summary testing)	1
5304	ETR 05-02-11 G1A Recovery Filter Femoral System Chronic Animal Study Report	1
5315	Phase 2 Design Review G1A Recovery Filter Femoral Delivery System	2
5316	Phase 3 Design Review (Design Review 3 & 4) G1A Recovery Filter Femoral Delivery System	2
5323	Aug. 8, 2005 FDA Grants BPV Conditional Approval for G2 Everest Study (G050134)	4
5324	July 8, 2005 BPV's original IDE submission re G2 Everest Study (G050134)	4
5325	Oct. 3, 2005 Letter BPV to FDA re G2 Everest Study (G051034) and Conditional Approval	4
5329	June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	4
5333	Feb. 2, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report	4
5334	Sept. 21, 2007 Letter FDA to BPV Questions re G2 Everest Study (G051304)	4
5335	Aug. 23, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report	4
5336	Oct. 25, 2007 Letter BPV to FDA re Responses to FDA re G2 Everest Study (G051304)	4
5340	Oct. 31, 2007 BPV's G2 Filter Retrievable Traditional 510(k) (K073090)	4
5344	July 28, 2005 Letter FDA to BPV re AI re Modified Recovery (K050558)	4
5349	Mar. 2, 2005 BPV's Modified Recovery Filter Special 510(k) (K050558)	4

5354	Sept. 19, 2005 BPV's G2 Filter - Jugular Subclavian Delivery Kit Special 510(k) (K052578)	4
5361	Sept. 25, 2006 BPV's G2 Filter - Femoral Delivery Kit Special 510(k) (K062887)	4
5483	sopq1417500 Rev 1 -- Statistical Complaint Trending Procedure PMA Related sopq1417500 Rev 1 -- Statistical Complaint Trending Procedure PMA Related	3
5526	TPR-04-02-02 (Protocol for RNF Migration Testing v. Competitive) Test Protocol Number TPR-04-02-02 (Rev. 0) -- Characterization of the Recovery Filter (RF) - Migration Resistance	1
5539	G2 Caudal Migration Failure Investigation Report Aug. 4, 2005 G2 Filter Caudal Migration Failure Investigation Report (FIR-06-01-01) G2 Caudal Migration Failure Investigation Report	3
5560	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 11	2
5602	FDA CONTACT REPORT January 7 2010 FINAL	4
5691	BPV FDA 483 Update Response March 26, 2015.pdf	4
5706	September 3 2015 Update Response to Warning Letter issued July 13 2015.pdf	4
5851	TD-04698 Re_Retrospective IVC Filter Review.pdf	2, 3
5872	FDA Warning Close Out Letter	4
5874	Bard filter rate information December 2016	3
5877	1996 Memo from Veronica Price	4
5879	April 11, 2006 Letter to FDA re Caudal Migration	4
5880	March 23, 2006 Letter to FDA re G2 Caudal Migration	4
5881	May 11, 2006 Letter to FDA re Caudal Migration	4
5942	January 7, 2010 FDA Powerpoint Presentation	4

5949	ETR-06-05-02 (Test report re G2® Clot Trapping Efficiency)	1
5994	TD-04316 Nov. 4, 2015 FDA and Bard Teleconference	4
5995	TD-04326 Oct. 26, 2015 FDA and Bard Teleconference	4
6046	August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	3
6061	Aug. 22, 2005 Internal FDA memo reviewing BPV's Responses to FDA AI re G2 (K050558)	4
6064	July 26, 2005 Internal FDA memo re BPV Responses to FDA AI re Modified Recovery (K050558)	4